Antifungal Treatment Market Research Report- Global Forecast till 2023

Report / Search Code: MRFR/HC/1097-CRR  Publish Date: August, 2017

Price

| Price          | 1-user PDF : $ 4450.0 | Enterprise PDF : $ 6250.0 |

Description:

Antifungal Treatment Market Information, By Drugs Class (Azoles, Pyrimidines, Echinocandins, Polynes, Allylamines, And Others), By Therapeutic Indication (Systemic, Candidiasis, Coccidioidomycosis, Cryptococcosis, And Prophylactic), By Pathogen (Candida, Aspergillus, Cryptococcus, Coccidioides Immitis, Zygomycetes, Trichophyton, And Others), And By End Users (Hospitals & Clinics, Dermatology Clinics, And Others) - Global Forecast Till 2023

FIGURE 1  Global antifungal treatment market by drug class 2016 (%)

Intended Audience:

- Antifungal drug manufacturers
- Antifungal drug suppliers
- Medical research laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting
Service Providers

- Potential Investors

Research Methodology:

![Research Methodology Diagram]

**Market synopsis of global anti-fungal treatment market:**

**Market Scenario**

Fungal infections such as athlete's foot, ringworm infection, serious systemic infections, and others are spreading rapidly across the globe and a number of treatments are available to treat these diseases. Rising incidence of immunological disease and availability of a wide range of products have driven the growth of the global antifungal treatment market. Furthermore, rising awareness about side effects of traditional drugs and availability of new drugs favor the growth of the market.

The global antifungal treatment market is expected to grow at a CAGR of 4.61% during the forecast period and is estimated to reach USD 19,558.0 million by 2023.

**Segments**

The global antifungal treatment market has been segmented on the basis of drugs class, which includes azoles, pyrimidines, echinocandins, polyenes, allylamines, and others drugs.

On the basis of therapeutic indication, the market is segmented into systemic, candidiasis, coccidioidomycosis, and cryptococcosis.

On the basis of pathogen, the market is segmented into *Candida, Aspergillus, Cryptococcus, Coccidioides immitis, Zygomyces, Trichophyton*, and others.

On the basis of end users, the market is segmented into hospitals & clinics, dermatology clinics and other users.

**Regional Analysis of Global Antifungal Treatment Market**
Considering the global scenario of the market, the Americas accounted for a significant market share in 2016, which was valued at USD 5,539.4 million as a result of increasing prevalence of immunological diseases and rising healthcare expenditure.

Europe is the second largest market and holds a noticeable share in the global antifungal treatment market. The European market is expected to grow significantly during the forecast period owing to availability of advanced treatment facilities, skilled medical professionals, and adoption of new therapies.

Increasing prevalence of HIV in Asia Pacific region is the key factor for the market growth. Rising awareness about the antifungal treatment and availability of new treatment methods drive the market in Asia Pacific region. In Asia Pacific, the market shows growth opportunities in China and India. China is expected to be the fastest growing market with the CAGR of 5.24% during the forecasted period.

The Middle East & Africa is expected to show the least growth in this market due to some major factors such as lack of awareness about the anti-fungal treatment, limited access and availability of treatment facilities, low income etc.

Key Findings

- Azoles segment in drug class held the largest market share in 2016, which was valued at USD 2,312.6 million in 2016

- Systemic segment in therapeutics indication held the largest market share in 2016.

- Asia Pacific region is expected to be the fastest growing market at the CAGR of 4.88% during the forecasted period.

Key Players in the Global Antifungal Treatment Market

Some of the key players in this market are Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), Merck & Co., Inc. (U.S), Astellas (Japan), Bayer AG (Germany)

The report on the Global Anti-fungal Treatment Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the
top key players in the industry. The report also gives a broad study of the different market segments and regions.
5.8.4 Threats

7 Global Antifungal Treatment Market, by Drug Class
   7.1 Introduction
   7.2 Azoles
   7.3 Echinocandins
   7.4 Polyenes
   7.5 Allylamines
   7.6 Pyrimidines
   7.7 Others

8 Global Antifungal Treatment Market, by Therapeutic Indications
   8.1 Introduction
   8.2 Systemic
   8.3 Candidiasis
   8.4 Cryptococcosis
   8.5 Prophylactic Use of Antifungals
   8.6 Coccioidiomycosis

9 Global Antifungal Treatment Market, by Pathogens
   9.1 Introduction
   9.2 Candida
   9.3 Aspergillus
   9.4 Cryptococcus
   9.5 Coccioides immitis
   9.6 Zygomycetes
   9.7 Trichophyton

10 Global Antifungal Treatment Market, by End User
    10.1 Introduction
    10.2 Hospitals & Clinics
    10.3 Dermatology Clinics
    10.4 Others

11 Global Antifungal Treatment Market, by Region
    11.1 Introduction
    11.2 Americas
    11.2.1 North America
    11.2.1.1 U.S.
    11.2.1.2 Canada
    11.2.2 South America
    11.3 Europe
    11.3.1 Western Europe
    11.3.1.1 Germany
    11.3.1.2 France
    11.3.1.3 U.K.
    11.3.1.4 Italy
    11.3.1.5 Spain
    11.3.2 Rest of Western Europe
    11.3.3 Eastern Europe
    11.4 Asia Pacific
    11.4.1 Japan
    11.4.2 China
    11.4.3 India
    11.4.4 Republic of Korea
    11.4.5 Australia
    11.4.6 Rest of Asia-Pacific
    11.5 The Middle East & Africa
    11.5.1 The Middle East
    11.5.2 Africa

12 Competitive Landscape
    12.1 Introduction
    12.2 Company Share Analysis

13 Company Profiles
    13.1 Pfizer, Inc.
    13.1.1 Company Overview
    13.1.2 Financials
13.1.3 Products
13.1.4 Strategy
13.1.5 Key Achievements
13.2 Astellas
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Products
13.2.4 Strategy
13.2.5 Key Achievements
13.3 Novartis AG.
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Products
13.3.4 Strategy
13.3.5 Key Achievements
13.4 Sanofi
13.4.1 Company Overview
13.4.2 Financials
13.4.3 Products
13.4.4 Strategy
13.4.5 Key Achievements
13.5 Merck & Co., Inc.
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Products
13.5.4 Strategy
13.5.5 Key Achievements
13.6 Bayer AG
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Products
13.6.4 Strategy
13.6.5 Key Achievements
13.7 Abbott
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Products
13.7.4 Strategy
13.7.5 Key Achievements
14 Conclusion
14.1 Key Findings
14.1.1 CEO's Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix